≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

See these related core endpoints for full statistics:

Use of peginterferon beta-1a

Endpoint Browser

MSMED_PEGINTERFERONBETA1A

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Medicine purchases: ATC — L03AB13

1 out of 7 registries used, show all original rules.

148

4. Check minimum number of events

Min. number of events 3
148

5. Include endpoints

None

148

6. Filter based on genotype QC (FinnGen only)

137

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

Not enough data for upset plot.

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 137 114 23
Unadjusted period prevalence (%) 0.04 0.04 0.01
Median age at first event (years) 40.48 38.44 50.58

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
148
Matched controls
1480
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L03AB13
ATC
peginterferon beta-1a; parenteral
+∞
213.9
148
*
109
Kela drug reimbursment
Multiple sclerosis
+∞
198.6
148
10
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
198.6
148
10
G35
ICD-10 Finland
Multiple sclerosis
+∞
195.2
148
13
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
2335.3
176.2
138
8
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
38.3
118.0
102
81
TAB00
NOMESCO Finland
Lumbar puncture
32.6
96.0
74
44
L03AB07
ATC
interferon beta-1a; parenteral
279.4
67.3
64
*
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
124.4
58.4
60
8
H46
ICD-10 Finland
Optic neuritis
128.1
49.6
51
6
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
12.3
47.1
60
78
L04AA31
ATC
[U] teriflunomide
+∞
44.0
40
*
N86
ICPC
Multiple sclerosis
481.6
38.9
37
*
XA800
NOMESCO Finland
Neuropsychological investigation
14.5
34.9
35
31
L04AX07
ATC
dimethyl fumarate; oral
94.1
33.6
36
5
L03AX13
ATC
glatiramer acetate; parenteral
90.7
32.5
35
5
N04BB01
ATC
amantadine; oral
358.4
29.9
29
*
N07XX09
ATC
[U] dimethyl fumarate
124.4
28.9
30
*
XCK00
NOMESCO Finland
Perimetry
11.7
24.9
28
29
L03AB08
ATC
interferon beta-1b; parenteral
270.1
23.3
23
*
G04BD12
ATC
mirabegron; oral
9.2
22.1
30
40
164
Kela drug reimbursment
Fingolimod
128.2
21.2
22
*
R20.2
ICD-10 Finland
Paraesthesia of skin
6.4
20.1
40
81
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
8.2
19.0
28
41
353
Kela drug reimbursment
Cladribine and fingolimod
101.8
17.0
18
*
2AB04, ,
NOMESCO Finland
190.6
16.9
17
*
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
8.2
16.6
24
34
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.9
16.3
45
121
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.2
15.6
30
58
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
28.6
15.1
20
8
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
22.0
14.7
21
11
ZX120
NOMESCO Finland
Intravenous
6.5
14.4
26
47
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
6.6
14.2
25
44
L04AA27
ATC
[U] fingolimod
+∞
13.8
13
*
XKD06
NOMESCO Finland
Physiologic investigation of micturition
23.9
13.7
19
9
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
17.6
13.0
20
13
L04AG12
ATC
ofatumumab; parenteral
+∞
12.7
12
*
L04AK02
ATC
teriflunomide; oral
+∞
12.7
12
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
11.6
12.5
23
23
XCW99
NOMESCO Finland
Other investigative procedure of eye
5.6
11.9
25
52
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
70.7
11.8
13
*
H02AB04
ATC
methylprednisolone; systemic
4.3
11.4
34
95
C10AC01
ATC
colestyramine; oral
15.6
11.3
18
13
L04AX09
ATC
diroximel fumarate; oral
+∞
10.5
10
*
XKD00
NOMESCO Finland
Uroflowmetry
7.9
9.8
22
32
R42
ICD-10 Finland
Dizziness and giddiness
3.6
9.6
38
129
XKC03
NOMESCO Finland
Water cystometry
15.0
9.4
15
11
G04BD09
ATC
trospium; oral
25.9
9.1
12
5
TKC22
NOMESCO Finland
Catheterisation instruction
53.2
8.8
10
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
5.2
8.6
19
41
XKD03
NOMESCO Finland
Urethral pressure profilometry
21.6
8.6
12
6
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
95.3
8.5
9
*
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
8.4
8.5
18
24
M03BX01
ATC
baclofen; systemic
14.1
8.0
13
10
N39.4
ICD-10 Finland
Other specified urinary incontinence
6.9
7.5
18
29
XCD10
NOMESCO Finland
Electrophysiological examination of eye
10.2
7.5
14
15
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
7.3
7
*
UKC02
NOMESCO Finland
Cystoscopy
4.1
7.2
21
57
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
10.1
6.9
13
14
Z2445
NOMESCO Finland
Psychologist
4.4
6.8
18
45
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
17.7
6.8
10
6
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
9.4
6.7
13
15
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
10.8
6.7
12
12
ZY010
NOMESCO Finland
Hospital outpatient
4.1
6.3
18
48
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
9.2
6.2
12
14
G04BD07
ATC
tolterodine; oral
9.2
6.2
12
14
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
13.3
6.2
10
8

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
42
29
19.82
48.79
1.0
1.2
—
—
—
0
0
41
31
17.91
45.27
1.3
1.2
—
—
—
0
0
38
33
15.15
38.51
1.0
1.2
86.97
35.79
e6/l
0.32
29
28
38
33
15.15
38.51
1.0
1.2
13.41
2.50
e6/l
1.98
29
26
135
581
16.07
32.74
9.4
5.5
—
—
—
0
0
137
611
17.71
31.67
9.9
5.2
0.49
0.52
e9/l
1.08
126
548
137
612
17.66
31.58
9.8
5.2
0.03
0.04
e9/l
2.79
126
545
37
12
40.50
29.89
1.6
1.5
—
—
—
0
0
137
638
16.44
29.38
9.9
5.8
0.18
0.18
e9/l
0.00
126
584
137
642
16.26
29.06
9.9
5.2
1.65
2.20
e9/l
2.36
126
591
134
698
10.72
22.73
10.5
7.9
3.02
3.97
e9/l
7.93
124
615
20
12
19.03
13.42
2.1
1.6
47.43
46.53
%
0.08
20
12
21
17
14.18
12.58
1.1
1.1
—
—
—
0
0
16
9
19.72
11.00
1.6
2.1
9.31
10.78
%
—
16
9
16
9
19.72
11.00
1.6
2.3
78.94
79.11
%
—
16
9
40
135
3.69
10.29
1.3
1.4
—
—
—
0
0
16
12
14.77
9.93
1.1
1.2
—
—
—
0
0
75
378
3.00
9.84
2.5
4.5
38.78
37.72
g/l
1.16
65
355
126
869
4.03
9.24
5.9
3.8
—
—
—
0
0
120
805
3.59
9.15
5.9
4.0
—
1900.86
—
0
7
93
544
2.91
9.00
10.9
6.8
0.00
0.00
e9/l
0.50
81
441
13
8
17.64
8.73
2.9
1.6
0.15
0.23
e9/l
—
13
8
14
13
11.75
7.98
2.9
2.2
831.79
939.92
e6/l
0.29
14
13
55
263
2.74
7.58
6.7
6.3
—
—
—
0
0
58
286
2.69
7.52
3.5
2.6
7.66
65.03
e6/l
1.71
49
206
148
1306
+∞
7.47
17.7
7.7
25.61
24.49
u/l
0.50
148
1266
142
1175
6.14
7.42
5.8
4.8
1.63
1.68
mu/l
0.24
142
1117
53
253
2.71
7.29
3.6
2.3
0.14
0.16
e6/l
0.07
45
179
53
264
2.57
6.60
3.6
2.4
—
—
—
0
0
48
231
2.60
6.39
1.4
1.5
—
—
—
0
0
17
33
5.68
6.24
1.2
1.3
—
—
—
0
0
66
374
2.38
6.13
5.0
3.1
3.87
57.79
e6/l
1.94
51
225
25
86
3.29
6.08
1.6
1.3
—
—
—
0
0
81
511
2.29
5.76
3.4
5.0
8.50
9.62
umol/l
1.37
76
486
8
7
11.98
4.84
1.3
2.1
27.50
26.43
%
—
8
7
31
140
2.54
4.58
3.6
2.2
2.00
4.75
e6/l
1.32
15
68
74
495
1.99
4.08
3.6
2.7
5.86
6.00
ph
—
7
51
7
8
9.11
3.81
1.1
1.1
1478.57
1478.00
miu/ml
—
7
8
52
318
1.98
3.62
2.7
2.2
—
—
—
0
0
31
163
2.14
3.21
2.5
2.4
3940.23
2688.75
u/l
—
10
73
53
341
1.86
3.10
1.6
1.7
89.20
94.05
pmol/l
0.46
32
186
9
21
4.49
3.05
1.0
1.0
—
—
—
0
0
81
596
1.79
3.04
6.6
4.4
0.00
0.00
estimate
-0.00
17
130
81
598
1.78
2.99
4.2
3.1
0.00
0.00
estimate
-0.00
18
132
14
52
2.87
2.98
1.1
2.2
56.59
71.71
e9/l
—
8
39
81
607
1.74
2.76
4.2
3.2
0.00
0.00
estimate
-0.00
17
125
64
454
1.72
2.62
1.7
1.8
—
—
—
0
0
9
25
3.76
2.62
1.6
3.9
54.00
54.76
%
—
9
25
9
25
3.76
2.62
1.6
3.7
2.60
3.57
e9/l
—
9
25
11
37
3.13
2.55
1.7
1.9
—
—
—
0
0
131
1151
2.20
2.48
19.1
11.6
14.01
14.00
%
0.01
131
1139
34
203
1.88
2.46
1.4
1.3
17.58
20.84
nmol/l
1.03
29
183
8
22
3.78
2.40
1.0
1.0
—
—
—
0
0
8
23
3.62
2.30
1.4
1.6
—
—
—
0
0
79
608
1.64
2.29
2.6
4.7
5.65
6.30
mmol/l
4.46
69
526
73
556
1.62
2.17
1.7
2.1
—
—
—
0
0
47
324
1.66
2.06
5.9
8.4
1.19
1.09
inr
0.34
16
120
138
1263
2.37
1.93
8.9
9.7
13.92
19.83
mg/l
1.84
92
947
148
1429
+∞
1.93
24.2
14.6
40.05
40.07
%
0.02
142
1367
148
1430
+∞
1.93
24.4
14.7
134.41
134.51
g/l
0.03
148
1413
148
1428
+∞
1.92
24.3
14.5
89.62
89.91
fl
0.41
148
1413
148
1428
+∞
1.92
24.2
14.5
29.89
30.04
pg
0.61
148
1412
38
254
1.67
1.86
4.6
3.1
—
—
—
0
0
6
18
3.43
1.76
1.2
1.1
—
—
—
0
0
44
314
1.57
1.65
1.8
1.3
2.22
2.21
g/l
0.03
34
201
103
883
1.55
1.63
2.6
3.4
8.56
7.97
mm/h
0.30
98
824
8
32
2.58
1.62
1.3
1.3
—
—
—
0
0
6
20
3.08
1.60
1.0
1.1
41.38
40.10
g/l
—
6
20
29
188
1.67
1.58
1.4
1.4
170.00
491.25
titre
—
8
32
9
42
2.22
1.36
1.6
1.6
—
—
—
0
0
108
1189
0.66
1.36
2.9
3.1
1.40
1.51
mmol/l
2.61
99
1131
109
1196
0.66
1.32
2.8
3.2
4.77
4.74
mmol/l
0.08
102
1138
5
117
0.41
1.32
2.6
1.6
—
—
—
0
0
11
199
0.52
1.29
1.4
1.2
—
—
—
0
0
8
35
2.36
1.29
2.5
3.7
139.88
134.60
g/l
—
8
35
8
35
2.36
1.29
2.8
2.0
—
—
—
0
0
103
1140
0.68
1.27
2.6
2.9
1.15
1.17
mmol/l
0.14
95
1077
5
19
2.69
1.22
1.2
1.3
—
—
—
0
0
38
280
1.48
1.21
1.6
1.9
2.51
2.88
mg/l
0.54
31
244
110
1199
0.68
1.19
2.8
3.3
2.94
2.85
mmol/l
0.57
100
1140
5
20
2.55
1.16
4.6
2.2
—
—
—
0
0
8
40
2.06
1.14
3.4
2.0
—
—
—
0
0
53
421
1.40
1.13
3.0
7.4
1.22
1.21
mmol/l
0.28
45
363
7
31
2.32
1.12
2.0
3.8
26.74
23.84
mmol/l
—
7
31
41
522
0.70
1.10
2.1
1.8
—
—
—
0
0
41
513
0.72
0.97
1.8
2.1
—
—
—
0
0
110
999
1.39
0.97
4.0
4.3
14.38
14.36
pmol/l
0.02
102
941
13
205
0.60
0.96
3.6
4.0
15.61
18.03
mg/mmol
—
7
129
30
225
1.42
0.87
3.2
2.3
—
—
—
0
0
13
199
0.62
0.86
3.6
3.5
6028.11
113.04
mg/l
—
7
133
18
255
0.67
0.84
1.4
1.5
—
—
—
0
0
6
34
1.80
0.77
2.3
1.3
—
—
—
0
0
9
58
1.59
0.71
2.4
3.2
—
—
—
0
0
16
112
1.48
0.67
5.5
3.3
—
—
—
0
0
5
28
1.81
0.67
2.0
2.0
0.70
0.65
%
—
5
28
44
367
1.28
0.65
3.6
2.6
—
—
—
0
0
35
283
1.31
0.65
1.4
1.7
0.50
0.68
mg/l
0.71
26
204
5
29
1.75
0.64
2.0
2.1
0.96
1.35
%
—
5
29
9
139
0.62
0.64
1.2
1.4
—
—
—
0
0
26
202
1.35
0.63
1.7
2.4
24.38
64.71
ug/g
2.89
16
160
45
380
1.26
0.60
1.6
1.9
—
—
—
0
0
35
287
1.29
0.59
2.0
2.4
7.43
15.86
ng/l
3.17
16
120
44
372
1.26
0.58
2.3
6.5
1.21
1.21
mmol/l
0.17
38
352
38
318
1.26
0.55
1.9
2.7
2.32
2.34
mmol/l
0.74
31
286
7
46
1.55
0.49
1.0
1.5
—
—
—
0
0
9
127
0.69
0.45
2.2
2.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
3.1
—
22.71
—
0
16
0
17
0.00
0.41
0.0
17.9
—
1733.94
—
0
17
0
17
0.00
0.41
0.0
12.1
—
880.88
—
0
17
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
11
82
1.37
0.35
1.1
1.1
—
—
—
0
0
6
44
1.38
0.35
2.3
1.7
—
—
—
0
0
11
140
0.77
0.29
1.6
2.9
0.86
0.83
mmol/l
0.57
11
134
16
131
1.25
0.28
1.3
1.2
—
—
—
0
0
8
63
1.29
0.28
1.1
1.4
—
—
—
0
0
11
138
0.78
0.27
1.0
1.2
—
—
—
0
0
9
74
1.23
0.26
1.9
4.2
—
—
—
0
0
7
91
0.76
0.23
2.0
7.3
1.02
1.00
mmol/l
—
7
83
10
79
1.29
0.23
2.6
7.5
105.10
105.70
mmol/l
—
10
79
0
11
0.00
0.21
0.0
1.3
—
1.48
—
0
11
0
10
0.00
0.21
0.0
1.2
—
194.24
—
0
10
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
3.7
—
20.69
—
0
10
0
10
0.00
0.21
0.0
1.1
—
227.63
—
0
10
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
0.85
—
0
12
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
2.3
—
8.34
—
0
14
0
14
0.00
0.20
0.0
1.5
—
125.57
—
0
7
0
14
0.00
0.20
0.0
1.5
—
—
—
0
0
108
1110
0.90
0.18
2.9
3.1
5.43
5.57
mmol/l
1.00
99
1045
8
70
1.15
0.16
1.3
1.1
—
—
—
0
0
6
75
0.79
0.16
1.0
1.1
—
—
—
0
0
19
170
1.13
0.14
2.1
2.7
30.78
316.43
ng/l
—
9
77
11
127
0.86
0.13
1.0
1.4
—
—
—
0
0
11
127
0.86
0.13
1.4
1.5
—
—
—
0
0
11
127
0.86
0.13
1.3
1.3
—
—
—
0
0
36
340
1.08
0.10
1.3
1.3
0.46
1.22
u/ml
—
5
93
52
499
1.06
0.10
2.1
1.7
—
—
—
0
0
5
47
1.07
0.09
1.2
1.5
—
—
—
0
0
23
246
0.92
0.08
1.2
1.3
14.92
9.39
u/ml
—
6
95
67
689
0.95
0.08
2.2
2.5
—
—
—
0
0
100
982
1.06
0.08
3.0
4.0
36.04
37.15
mmol/mol
0.86
91
942
6
71
0.84
0.08
1.7
1.7
—
—
—
0
0
6
70
0.85
0.08
1.3
1.2
—
—
—
0
0
24
226
1.07
0.07
1.8
2.1
—
—
—
0
0
9
101
0.88
0.06
1.2
1.4
—
—
—
0
0
9
101
0.88
0.06
1.2
1.4
—
—
—
0
0
9
100
0.89
0.06
1.2
1.4
—
—
—
0
0
9
102
0.87
0.06
1.2
1.4
—
—
—
0
0
14
129
1.09
0.06
1.3
1.2
—
—
—
0
0
42
406
1.05
0.05
1.5
1.7
—
—
—
0
0
30
307
0.97
0.01
4.7
3.3
0.00
0.00
estimate
-0.00
17
129
12
126
0.95
0.00
1.2
1.4
—
—
—
0
0
12
126
0.95
0.00
1.2
1.4
—
—
—
0
0
24
246
0.97
0.00
1.2
1.3
22.20
19.87
iu/ml
—
5
74
21
206
1.02
0.00
3.0
3.3
—
—
—
0
0
13
129
1.01
0.00
1.2
1.5
—
—
—
0
0
16
161
0.99
0.00
1.1
1.3
184.00
143.66
iu/ml
—
7
66
10
98
1.02
0.00
1.0
1.1
—
—
—
0
0
9
99
0.90
-0.00
2.3
2.6
0.79
1.62
ug/l
—
9
88
0
5
0.00
-0.00
0.0
4.0
—
13.90
—
0
5
0
8
0.00
-0.00
0.0
1.0
—
8.32
—
0
8
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
8
80
1.00
-0.00
1.3
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
33.2
—
6.63
—
0
6
0
7
0.00
-0.00
0.0
1.6
—
8.20
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
10.46
—
0
5
0
6
0.00
-0.00
0.0
3.2
—
1.72
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
5.7
—
6.67
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
141.40
—
0
5
0
5
0.00
-0.00
0.0
2.4
—
0.91
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
33.50
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
6.00
—
0
5
0
6
0.00
-0.00
0.0
2.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
493.17
—
0
6
7
71
0.99
-0.00
1.9
2.7
—
—
—
0
0
6
65
0.92
-0.00
2.3
2.0
14.48
10.20
nmol/l
—
6
60
6
60
1.00
-0.00
4.2
3.0
—
—
—
0
0
9
93
0.97
-0.00
1.2
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.7
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: MSMED_PEGINTERFERONBETA1A – Use of peginterferon beta-1a

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).